Join the Lupus Erythematosus group to help and get support from people like you.
Lupus Erythematosus News
Related terms: Discoid Lupus Erythematosus, DLE
Pericarditis Recurrence Occurs in About 20 Percent of Patients With Lupus
TUESDAY, March 4, 2025 – For patients with systemic lupus erythematosus (SLE) and pericarditis, recurrence of pericarditis occurs in more than 20 percent of patients and associated factors include...
Anifrolumab Tied to Less Organ Damage for Patients With Lupus
THURSDAY, Feb. 20, 2025 – For patients with moderately to severely active systemic lupus erythematosus (SLE), anifrolumab is associated with less organ damage after 208 weeks compared with patients...
Saphnelo Can Stave Off Organ Damage From Lupus
WEDNESDAY, Feb. 19, 2025 – Lupus can do irreversible harm to a person’s organs, damaging the lungs, kidneys, heart, liver and other vital organs through inflammation. But a newer lupus drug appears t...
People With Lupus Are At Risk for This Type of Heart Disease
WEDNESDAY, Jan. 15, 2024 – People with lupus-related skin problems are more likely to develop heart disease associated with hardening of the arteries. Lupus patients with skin symptoms are 72% more...
Air Pollutant Exposure Linked to Increased Risk for Incident Lupus
WEDNESDAY, July 10, 2024 – Air pollutant exposure is associated with an increased likelihood of developing incident systemic lupus erythematosus (SLE), according to a study published online July 10...
Scientists Spot Cause of Lupus, Way to Reverse It
THURSDAY, July 11, 2024 – Lupus is caused by a specific defect in the immune system that can be reversed, potentially curing the autoimmune disorder, a new study claims. The disease appears to be...
Air Pollutant Exposure Linked to Increased Risk for Incident Lupus
WEDNESDAY, July 10, 2024 – Air pollutant exposure is associated with an increased likelihood of developing incident systemic lupus erythematosus (SLE), according to a study published online July 10...
FDA Approves Belimumab Autoinjector for Pediatric Systemic Lupus Erythematosus
WEDNESDAY, May 22, 2024 – The U.S. Food and Drug Administration has approved a 200-mg subcutaneous route of administration of Benlysta (belimumab) for patients 5 years of age and older with active...
FDA Approves Benlysta (belimumab) Autoinjector for Children with Systemic Lupus Erythematosus
Philadelphia, PA May 20 2024 – GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved a 200 mg subcutaneous route of administration of Benlysta...
GSK Receives US Approval of Benlysta for Intravenous Use in Children with Lupus Aged Five Years and Above
London UK, Philadelphia USA April 26, 2019 – GSK today announced that the US Food and Drug Administration (FDA) has approved, under priority review, the use of the intravenous (IV) formulation of...
GSK Receives FDA Approval for a New Self-Injectable Formulation of Benlysta (belimumab) for Systemic Lupus Erythematosus
London, UK 21 July 2017 – GSK announced today that the US Food and Drug Administration (FDA) has approved a new subcutaneous formulation of Benlysta (belimumab) for the treatment of adult patients...
FDA Approves Benlysta to Treat Lupus
March 9, 2011 – The U.S. Food and Drug Administration today approved Benlysta (belimumab) to treat patients with active, autoantibody-positive lupus (systemic lupus erythematosus) who are receiving...
Further information
Related condition support groups
Systemic Lupus Erythematosus, Autoimmune Disorders